Astellas Buys Eligard European Marketing, Distribution Rights From MediGene
As per the contract, Astellas is expected to pay EUR25m in three tranches as the steps of transfer of the rights are expected to be concluded over the
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.